Cited by 239Lysosomal Storage Disorders ResearchAmyotrophic Lateral Sclerosis ResearchAlzheimer's disease research and treatments

The lysosomal function of progranulin, a guardian against neurodegeneration

Open access
Paushter, Daniel H., Du, Huan, Feng, Tuancheng, Hu, Fenghua·2018·Acta Neuropathologica

Abstract

Progranulin (PGRN), encoded by the GRN gene in humans, is a secreted growth factor implicated in a multitude of processes ranging from regulation of inflammation to wound healing and tumorigenesis. The clinical importance of PGRN became especially evident in 2006, when heterozygous mutations in the GRN gene, resulting in haploinsufficiency, were found to be one of the main causes of frontotemporal lobar degeneration (FTLD). FTLD is a clinically heterogenous disease that results in the progressive atrophy of the frontal and temporal lobes of the brain. Despite significant research, the exact function of PGRN and its mechanistic relationship to FTLD remain unclear. However, growing evidence suggests a role for PGRN in the lysosome-most striking being that homozygous GRN mutation leads to neuronal ceroid lipofuscinosis, a lysosomal storage disease. Since this discovery, several links between PGRN and the lysosome have been established, including the existence of two independent lysosomal trafficking pathways, intralysosomal processing of PGRN into discrete functional peptides, and direct and indirect regulation of lysosomal hydrolases. Here, we summarize the cellular functions of PGRN, its roles in the nervous system, and its link to multiple neurodegenerative diseases, with a particular focus dedicated to recent lysosome-related mechanistic developments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-018-1861-8

Cites

161 of 161 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. [14]Beutler E Grabowski G 1995 Guacher disease 7 The Metabolic Basis of Inherited Disease McGraw-Hill New York
  2. [19]Butler GS Dean RA Tam EM Overall CM 2008 Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding Molecular and cellular biology 28 4896 4914 10.1128/MCB.01775-07 18505826 PMC2493375 · DOI
  3. [100]Pottier C Ravenscroft TA Sanchez-Contreras M Rademakers R 2016 Genetics of FTLD: Overview and what else we can expect from genetic studies J Neurochem 10.1111/jnc.13622 27009575 · DOI · Paper page
  4. [145]Xu D Suenaga N Edelmann MJ Fridman R Muschel RJ Kessler BM 2008 Novel MMP-9 substrates in cancer cells revealed by a label-free quantitative proteomics approach Mol Cell Proteomics PMC2577209 18596065

Cited by

Sorted by citations

Authors
Paushter, D. H., Du, H., Feng, T., & Hu, F.
Affiliations
Cornell University (US)
Corresponding author
Hu, Fenghua
Venue
Acta Neuropathologica
Published
2018-05-09
Volume
136
Issue
1
Pages
1-17
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2802961407
Cited by
230
References
161
Citations by year
2026: 21 · 2025: 31 · 2024: 33 · 2023: 32 · 2022: 26 · 2021: 45 · 2020: 19 · 2019: 18 · 2018: 3 · 2017: 1
FWCI
2.79
Type
journal article
Language
en
Open access
Locations
  • Acta Neuropathologica (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Neurological Disorders and Stroke (R01NS088448, R01NS095954)
Topics
  • Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
progranulin, lysosomes, lysosomal trafficking, frontotemporal lobar degeneration, haploinsufficiency, neuronal ceroid lipofuscinosis, lysosomal storage disease, lysosomal enzymes, neurodegeneration, neurodegenerative diseases
MeSH terms
Progranulins, Animals, Humans, Lysosomes, Models, Biological, Mutation, Neurodegenerative Diseases, Protein Transport

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review